Zymeworks Appoints Kristin Stafford as CFO Effective April 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 01 2026
0mins
Should l Buy ZYME?
Source: seekingalpha
- Executive Change: Zymeworks has appointed Kristin Stafford as Chief Financial Officer effective April 1, 2026, bringing her experience from Royalty Pharma where she served as Senior Vice President and Chief Accounting Officer, which is expected to enhance the company's financial management capabilities.
- Financial Performance Review: In its Q4 2025 earnings report, Zymeworks reported a GAAP EPS of -$0.55, missing expectations by $0.21, indicating challenges in achieving profitability and raising concerns among investors.
- Revenue Shortfall: The company reported revenue of $2.52M, falling short of market expectations by $18.01M, highlighting significant deficiencies in revenue growth that could impact investor confidence moving forward.
- Strategic Outlook: Zymeworks signals a milestone-driven expansion strategy with a potential of up to $1.5 billion by 2028, indicating a commitment to long-term growth despite current financial struggles.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ZYME?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ZYME
Wall Street analysts forecast ZYME stock price to rise
14 Analyst Rating
14 Buy
0 Hold
0 Sell
Strong Buy
Current: 26.000
Low
30.00
Averages
35.55
High
42.00
Current: 26.000
Low
30.00
Averages
35.55
High
42.00
About ZYME
Zymeworks Inc. is a global clinical-stage biotechnology company. The Company is developing a diverse pipeline of multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases such as cancer, autoimmune and inflammatory diseases (AIID). The Company engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s Azymetric technology. It has entered into separate agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. It is advancing a pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company has two clinical-stage product candidates: ZW171 and ZW191. Its preclinical product candidates include ZW251, ZW220, ZW209, and ZW1528.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Zymeworks Appoints New Heads of R&D and Business
- Executive Appointments: Zymeworks has officially appointed Dr. Adam Schayowitz as Head of R&D and Mr. Scott Platshon as Chief Business Officer as of April 9, 2026, aiming to enhance the company's execution and strategic positioning in the biotherapeutics sector.
- R&D Strategy: Dr. Schayowitz will leverage nearly two decades of oncology drug development experience to advance the clinical progression of the company's product candidates, particularly in areas of high unmet need, thereby enhancing the company's competitive edge in the market.
- Asset Management: Mr. Platshon is tasked with managing Zymeworks' asset aggregation strategy, which is expected to drive cash flows from products like Ziihera®, contributing to long-term shareholder value growth.
- Strategic Integration: These executive changes align with Zymeworks' overall strategy, aiming to optimize future cash flows and support ongoing investments in innovative therapeutics through the integration of R&D innovation and strategic collaborations.
See More
Zymeworks Appoints Kristin Stafford as CFO Effective April 2026
- Executive Change: Zymeworks has appointed Kristin Stafford as Chief Financial Officer effective April 1, 2026, bringing her experience from Royalty Pharma where she served as Senior Vice President and Chief Accounting Officer, which is expected to enhance the company's financial management capabilities.
- Financial Performance Review: In its Q4 2025 earnings report, Zymeworks reported a GAAP EPS of -$0.55, missing expectations by $0.21, indicating challenges in achieving profitability and raising concerns among investors.
- Revenue Shortfall: The company reported revenue of $2.52M, falling short of market expectations by $18.01M, highlighting significant deficiencies in revenue growth that could impact investor confidence moving forward.
- Strategic Outlook: Zymeworks signals a milestone-driven expansion strategy with a potential of up to $1.5 billion by 2028, indicating a commitment to long-term growth despite current financial struggles.
See More
Zymeworks Appoints New CFO, Stock Rises
- Executive Appointment: Zymeworks has appointed Kristin Stafford as Chief Financial Officer, bringing extensive experience from her previous role as Senior Vice President and Chief Accounting Officer at Royalty Pharma plc, which is expected to enhance the company's financial management.
- Stock Performance: Following the announcement, Zymeworks' stock rose by $0.66, or 2.64%, in pre-market trading, indicating market optimism regarding the new CFO and confidence in the company's future growth.
- FDA Fast Track Designation: On Monday, Zymeworks received FDA fast track designation for its antibody-drug conjugate ZW191, targeting advanced or metastatic platinum-resistant ovarian cancer, marking a significant advancement in the company's biotherapeutics pipeline that could expedite its market entry.
- Market Outlook: With the fast track designation for ZW191, Zymeworks significantly enhances its market potential in cancer and autoimmune disease treatments, likely attracting more investor interest and further driving up the company's stock price.
See More
Zymeworks Appoints Kristin Stafford as CFO
- Executive Appointment: Zymeworks has appointed Kristin Stafford as Chief Financial Officer, effective April 1, 2026, bringing extensive experience from the life sciences sector, particularly from her role at Royalty Pharma, where she excelled in strategic planning and capital allocation, which is expected to enhance the company's financial stability and strategic execution.
- Strategic Background: During her tenure at Royalty Pharma, Stafford successfully executed complex capital market transactions and acquisitions, demonstrating her strong background in capital markets, which will provide crucial support for Zymeworks' capital operations and market expansion.
- Business Development: Zymeworks focuses on developing multifunctional biotherapeutics, and Stafford's expertise will help optimize the company's asset portfolio and cash flows, particularly in its innovative drug pipeline, enhancing its position in the competitive biotechnology market.
- Future Outlook: Zymeworks plans to leverage Stafford's leadership to strengthen capital allocation and operational excellence, driving long-term value creation, especially in the development of treatment solutions for difficult-to-treat diseases, showcasing the company's confidence in future growth.
See More
Zymeworks' Investigational Drug ZW191 Receives FDA Fast Track Designation
- FDA Fast Track Designation: Zymeworks' investigational drug ZW191 has received Fast Track designation from the FDA for treating advanced or metastatic platinum-resistant ovarian cancer, highlighting the program's potential to address significant unmet medical needs.
- Clinical Trial Progress: A Phase I trial of ZW191 in patients with advanced solid tumors is currently underway, which is expected to expedite the drug development process and provide faster treatment options for patients.
- Positive Market Reaction: Following the announcement, Zymeworks' stock price rose over 3% to $24.73 in premarket trading on Monday, indicating investor optimism regarding the drug's prospects.
- Broad Applicability: As an antibody-drug conjugate targeting folate receptors, ZW191 shows potential for treating various tumor types, particularly benefiting approximately 75% of high-grade serous ovarian carcinoma patients, indicating its wide applicability in the treatment landscape.
See More
Zymeworks Receives FDA Fast Track Designation for ZW191
- FDA Fast Track Designation: Zymeworks announced that its antibody-drug conjugate ZW191 has received Fast Track designation from the FDA for the treatment of advanced or metastatic platinum-resistant ovarian cancer patients, marking a significant advancement in the company's oncology portfolio.
- Targeted Therapy Potential: ZW191 targets the folate receptor-a protein, which is expressed in various tumor types, including approximately 75% of high-grade serous ovarian carcinomas, over 50% of endometrial cancers, and about 70% of lung adenocarcinomas, indicating its broad applicability.
- Unique Design Advantages: The design of ZW191 allows it to effectively internalize into FRa-expressing cells and release the novel proprietary payload ZD06519, which has the potential to kill tumor cells, thereby providing new treatment options for patients.
- Clinical Trial Progress: Zymeworks is currently conducting a Phase 1 clinical study of ZW191 to assess its safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity, which will inform future development strategies based on the data collected.
See More
Zymeworks Appoints New Heads of R&D and Business
- Executive Appointments: Zymeworks has officially appointed Dr. Adam Schayowitz as Head of R&D and Mr. Scott Platshon as Chief Business Officer as of April 9, 2026, aiming to enhance the company's execution and strategic positioning in the biotherapeutics sector.
- R&D Strategy: Dr. Schayowitz will leverage nearly two decades of oncology drug development experience to advance the clinical progression of the company's product candidates, particularly in areas of high unmet need, thereby enhancing the company's competitive edge in the market.
- Asset Management: Mr. Platshon is tasked with managing Zymeworks' asset aggregation strategy, which is expected to drive cash flows from products like Ziihera®, contributing to long-term shareholder value growth.
- Strategic Integration: These executive changes align with Zymeworks' overall strategy, aiming to optimize future cash flows and support ongoing investments in innovative therapeutics through the integration of R&D innovation and strategic collaborations.
See More
Zymeworks Appoints Kristin Stafford as CFO Effective April 2026
- Executive Change: Zymeworks has appointed Kristin Stafford as Chief Financial Officer effective April 1, 2026, bringing her experience from Royalty Pharma where she served as Senior Vice President and Chief Accounting Officer, which is expected to enhance the company's financial management capabilities.
- Financial Performance Review: In its Q4 2025 earnings report, Zymeworks reported a GAAP EPS of -$0.55, missing expectations by $0.21, indicating challenges in achieving profitability and raising concerns among investors.
- Revenue Shortfall: The company reported revenue of $2.52M, falling short of market expectations by $18.01M, highlighting significant deficiencies in revenue growth that could impact investor confidence moving forward.
- Strategic Outlook: Zymeworks signals a milestone-driven expansion strategy with a potential of up to $1.5 billion by 2028, indicating a commitment to long-term growth despite current financial struggles.
See More
Zymeworks Appoints New CFO, Stock Rises
- Executive Appointment: Zymeworks has appointed Kristin Stafford as Chief Financial Officer, bringing extensive experience from her previous role as Senior Vice President and Chief Accounting Officer at Royalty Pharma plc, which is expected to enhance the company's financial management.
- Stock Performance: Following the announcement, Zymeworks' stock rose by $0.66, or 2.64%, in pre-market trading, indicating market optimism regarding the new CFO and confidence in the company's future growth.
- FDA Fast Track Designation: On Monday, Zymeworks received FDA fast track designation for its antibody-drug conjugate ZW191, targeting advanced or metastatic platinum-resistant ovarian cancer, marking a significant advancement in the company's biotherapeutics pipeline that could expedite its market entry.
- Market Outlook: With the fast track designation for ZW191, Zymeworks significantly enhances its market potential in cancer and autoimmune disease treatments, likely attracting more investor interest and further driving up the company's stock price.
See More
Zymeworks Appoints Kristin Stafford as CFO
- Executive Appointment: Zymeworks has appointed Kristin Stafford as Chief Financial Officer, effective April 1, 2026, bringing extensive experience from the life sciences sector, particularly from her role at Royalty Pharma, where she excelled in strategic planning and capital allocation, which is expected to enhance the company's financial stability and strategic execution.
- Strategic Background: During her tenure at Royalty Pharma, Stafford successfully executed complex capital market transactions and acquisitions, demonstrating her strong background in capital markets, which will provide crucial support for Zymeworks' capital operations and market expansion.
- Business Development: Zymeworks focuses on developing multifunctional biotherapeutics, and Stafford's expertise will help optimize the company's asset portfolio and cash flows, particularly in its innovative drug pipeline, enhancing its position in the competitive biotechnology market.
- Future Outlook: Zymeworks plans to leverage Stafford's leadership to strengthen capital allocation and operational excellence, driving long-term value creation, especially in the development of treatment solutions for difficult-to-treat diseases, showcasing the company's confidence in future growth.
See More
Zymeworks' Investigational Drug ZW191 Receives FDA Fast Track Designation
- FDA Fast Track Designation: Zymeworks' investigational drug ZW191 has received Fast Track designation from the FDA for treating advanced or metastatic platinum-resistant ovarian cancer, highlighting the program's potential to address significant unmet medical needs.
- Clinical Trial Progress: A Phase I trial of ZW191 in patients with advanced solid tumors is currently underway, which is expected to expedite the drug development process and provide faster treatment options for patients.
- Positive Market Reaction: Following the announcement, Zymeworks' stock price rose over 3% to $24.73 in premarket trading on Monday, indicating investor optimism regarding the drug's prospects.
- Broad Applicability: As an antibody-drug conjugate targeting folate receptors, ZW191 shows potential for treating various tumor types, particularly benefiting approximately 75% of high-grade serous ovarian carcinoma patients, indicating its wide applicability in the treatment landscape.
See More
Zymeworks Receives FDA Fast Track Designation for ZW191
- FDA Fast Track Designation: Zymeworks announced that its antibody-drug conjugate ZW191 has received Fast Track designation from the FDA for the treatment of advanced or metastatic platinum-resistant ovarian cancer patients, marking a significant advancement in the company's oncology portfolio.
- Targeted Therapy Potential: ZW191 targets the folate receptor-a protein, which is expressed in various tumor types, including approximately 75% of high-grade serous ovarian carcinomas, over 50% of endometrial cancers, and about 70% of lung adenocarcinomas, indicating its broad applicability.
- Unique Design Advantages: The design of ZW191 allows it to effectively internalize into FRa-expressing cells and release the novel proprietary payload ZD06519, which has the potential to kill tumor cells, thereby providing new treatment options for patients.
- Clinical Trial Progress: Zymeworks is currently conducting a Phase 1 clinical study of ZW191 to assess its safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity, which will inform future development strategies based on the data collected.
See More
